DARE — Dare Bioscience Share News
0.000.00%
Last trade - 00:00- $12.70m
- $5.98m
- $1.03m
Dare Bioscience Inc reports results for the quarter ended in June - Earnings Summary
Brief: Daré Bioscience Announces Findings For The Treatment Of Menopausal Symptoms From A Phase 1/2 Clinical Trial Of DARE-HRT1 Intravaginal Rings
Dare Bioscience Inc expected to post a loss of 10 cents a share - Earnings Preview
Dare Bioscience Inc expected to post a loss of 10 cents a share - Earnings Preview
Brief: Dare Bioscience Says On July 19, Co Got Notice Of Failure To Satisfy Continued Listing Rule Or Standard Transfer Of Listing From Nasdaq
Brief: Daré Bioscience Announces Additional Positive Data From Exploratory Phase 2B Respond Study Of Sildenafil Cream
Brief: Daré Bioscience Announces Upcoming Webinar To Review Additional Data From Exploratory Phase 2b Respond Study Of Sildenafil Cream, 3.6% In Women With Female Sexual Arousal Disorder
Brief: Daré Bioscience Provides Update On Activities To Support Commercial Launch Of XACIATO Vaginal Gel, 2%, FDA-Approved Treatment For Females 12 And Older With Bacterial Vaginosis
Brief: Daré Bioscience Announces Publication Of Phase 1/2 Pharmacokinetic, Safety And Pharmacodynamic Data For Dare-VVA1 - A Potential New Hormone-Free Treatment For Vulvovaginal Atrophy - In Climacteric, The Journal Of The International Menopause Society
Brief: Daré Bioscience Announces Positive Topline Data From The Mid-Stage Study Of Sildenafil Cream
Brief: Dare Bioscience Inc Reports Quarterly Loss Per Share Of $0.09
Dare Bioscience Inc expected to post a loss of 10 cents a share - Earnings Preview
Brief: Daré Bioscience Announces Initiation Of Subject Enrollment In A Phase 1 Thermography Study To Support Pharmacodynamic And Pharmacokinetic Characterization Of Sildenafil Cream, 3.6%
Brief: Daré Bioscience Announces Publication Of Data From Phase 1 Clinical Trial That Support The Potential Of Dare-Hrt1 Intravaginal Ring As A New Menopausal Hormone Therapy
Dare Bioscience Inc reports results for the quarter ended in December - Earnings Summary
Brief: Daré Bioscience Reports 2022 Loss Per Share Of $0.37
Dare Bioscience Inc expected to post a loss of 14 cents a share - Earnings Preview
RCS - Gibson Oncology, LLC - Gibson Oncology Expands its Board of Directors
Brief: Daré Bioscience Announces Start Of A Phase 1 Study For Its Potential First-In-Category Treatment For Primary Dysmenorrhea, Dare-Pdm1